A new 60-minute point-of-care lateral flow assay featured the same sensitivity as mycobacterial culture in detecting tuberculosis meningitis (TBM) in adult patients with HIV, according to a study in Clinical Infectious Diseases.

Wave 9 to address shortcomings in drug-resistant TB care - linkage to care, uptake of novel treatment regimens and treatment outcomes.

Novel approach for minimizing investment risks and stretching limited budgets has 375 innovations targeting infectious diseases under development.

Lack of access to COVID-19 vaccines for people in the world’s poorest countries echoes the health inequity faced by people affected by TB.

Treatment of drug-resistant forms of tuberculosis (DR-TB) in South Africa has been transformed over the last decade. Most people with DR-TB no longer have to take daily injections and treatment is often completed in nine months, compared to 18 to 24 months in the past. Maybe most importantly, fewer people are dying of DR-TB and fewer people are suffering hearing loss, a common side effect of injections used in the past.

On 21 January 2021, Treatment Action Group and partners conducted a webinar on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and advanced HIV disease (AHD).

In December 2020, more than 150 TB-affected community and civil society partners from over 60 countries released a report, A Deadly Divide: TB Commitments versus TB Realities, evaluating the progress towards fulfilling the targets and commitments contained within the UN Political Declaration on TB.

The National Institutes of Health has awarded $434,787 to Worcester Polytechnic Institute (WPI) to identify and assess compounds from the sweet wormwood plant that kill the bacteria that causes tuberculosis.